Pet Osteoarthritis Treatment Market Forecasts to 2034 - Global Analysis By Treatment Type, Drug Class, Pet Type, Distribution Channel, and By Geography

According to Stratistics MRC, the Global Pet Osteoarthritis Treatment Market is accounted for $3.3 billion in 2026 and is expected to reach $6.1 billion by 2034 growing at a CAGR of 8% during the forecast period. Pet osteoarthritis treatment encompasses pharmaceutical, biological, nutritional, and rehabilitative interventions designed to manage joint pain, inflammation, mobility limitations, and functional decline in companion animals. The market includes pharmaceuticals, biologics and regenerative therapies, nutraceuticals and joint supplements, and rehabilitation and physical therapy. Treatment options include nonsteroidal anti-inflammatory drugs (NSAIDs), analgesics, anti-nerve growth factor therapies, and other pain-management drugs, primarily serving dogs and cats through veterinary hospitals and clinics, veterinary pharmacies, and online pharmacies. Increasing pet longevity, growing awareness of animal pain management, and advances in veterinary therapeutics are supporting market development.

Market Dynamics:

Driver:

Increasing prevalence of osteoarthritis in aging companion animals

The growing population of aging companion animals is a major driver of the pet osteoarthritis treatment market. Osteoarthritis is a chronic degenerative joint condition that can cause persistent pain, stiffness, reduced mobility, and difficulty performing everyday activities. As dogs and cats live longer, demand for veterinary assessment and long-term pain management is increasing. Greater awareness among pet owners of mobility changes and age-related joint disorders is encouraging earlier veterinary consultations. Advances in pharmaceutical treatments, including targeted biological therapies and established anti-inflammatory medications, are expanding the available treatment options. Additionally, increasing expenditure on companion animal healthcare is supporting demand for prescription medications, joint supplements, and supportive rehabilitation services.

Restraint:

High treatment costs and limitations associated with long-term medication use

The cost of managing pet osteoarthritis can constrain treatment uptake, particularly when animals require ongoing medication, veterinary consultations, diagnostic examinations, and rehabilitation. Biological therapies and newer targeted treatments may involve higher costs than conventional medications, potentially limiting access among price-sensitive pet owners. Long-term pharmaceutical management also requires appropriate veterinary supervision because treatment suitability, contraindications, and adverse effects vary across animals. NSAIDs may require monitoring of gastrointestinal, kidney, and liver health, while other therapies have their own safety considerations. In addition, owners may delay treatment when early symptoms are subtle or difficult to distinguish from normal age-related changes, potentially increasing the complexity of subsequent care.

Opportunity:

Advancements in biological therapies and multimodal osteoarthritis management

Advances in targeted veterinary medicines and multimodal treatment approaches are creating opportunities for market participants. Anti-NGF monoclonal antibody therapies provide an alternative mechanism for managing osteoarthritis-associated pain, while pharmaceutical treatments, nutritional supplements, weight management, and physical rehabilitation can contribute to individualized care plans. The introduction of longer-acting therapies may also reduce the frequency of treatment administration and improve convenience for eligible patients. Additionally, research into regenerative medicine, including cell-based approaches and other biological interventions, is expanding the range of potential treatment options. Growing investment in veterinary clinical research, diagnostic capabilities, and professional education can further support innovation and adoption across companion animal healthcare markets.

Threat:

Regulatory scrutiny and competition among treatment alternatives

The pet osteoarthritis treatment market faces challenges from regulatory requirements, product safety monitoring, and competition among pharmaceutical and non-pharmaceutical interventions. Veterinary medicines must demonstrate appropriate safety, efficacy, and quality for their intended indications, while post-marketing surveillance can lead to labeling updates and changes in prescribing practices. Established NSAIDs compete with newer targeted therapies, supplements, rehabilitation services, and other supportive approaches. Differences in treatment response among individual animals can also influence veterinary and owner preferences. Furthermore, product development and clinical evaluation require substantial investment, while patent protection, commercialization costs, and market access requirements can affect competitive positioning. Manufacturers must maintain confidence through transparent safety communication and continued clinical evidence generation.

Covid-19 Impact:

The COVID-19 pandemic affected veterinary healthcare through temporary clinic restrictions, changes in appointment availability, supply chain disruptions, and shifts in household spending. Some routine veterinary consultations and elective assessments were postponed, potentially delaying the diagnosis and management of chronic conditions such as osteoarthritis. At the same time, increased time spent at home heightened some pet owners' awareness of companion animal health and mobility. Veterinary practices increasingly adopted digital communication and appointment management tools, while online purchasing gained importance for certain pet healthcare products. Following the pandemic, the continued focus on preventive veterinary care, pet longevity, and quality of life has supported demand for chronic pain management, prescription therapies, and supportive treatment services.

The Pharmaceuticals segment is expected to be the largest during the forecast period

The Pharmaceuticals segment is expected to account for the largest market share during the forecast period, supported by the established use of prescription medications to manage osteoarthritis-associated pain and inflammation in companion animals. NSAIDs and other analgesics remain important treatment options for eligible dogs and cats, with veterinary professionals selecting therapies according to the animal's condition, medical history, and treatment response. The availability of established brands and newer targeted medicines supports pharmaceutical demand across veterinary hospitals and clinics. In addition, chronic disease management often requires ongoing treatment and follow-up consultations, contributing to recurring demand for veterinary medications. Continued innovation in pain-management therapies is further strengthening the pharmaceutical treatment landscape.

The Biologics and Regenerative Therapies segment is expected to witness strong growth during the forecast period

The Biologics and Regenerative Therapies segment is expected to experience strong growth as veterinary medicine advances toward targeted approaches for managing chronic joint pain. Anti-NGF monoclonal antibody therapies have expanded treatment options for canine and feline osteoarthritis, offering a mechanism distinct from conventional NSAIDs. Longer-acting biological products may improve convenience by reducing administration frequency, while continued research into regenerative medicine is generating interest in approaches intended to support joint function and tissue health. Growing awareness of chronic pain management, increasing demand for individualized treatment, and continued investment in veterinary therapeutics are supporting segment development.

The Anti-Nerve Growth Factor Therapies segment is expected to witness strong growth during the forecast period

The Anti-Nerve Growth Factor Therapies segment is expected to record strong growth as veterinary medicine increasingly adopts targeted biological treatments for osteoarthritis-associated pain. These therapies act on nerve growth factor, a protein involved in pain signaling, and provide an alternative to conventional anti-inflammatory medication for eligible companion animals. Products such as Librela for dogs and Solensia for cats have established anti-NGF treatment options in major veterinary markets. The introduction of additional long-acting therapies, including newer products designed to provide pain relief for longer intervals, is broadening the treatment landscape. Greater veterinary familiarity with targeted therapeutics and increasing attention to chronic pain management are expected to support segment expansion.

Region with largest share:

During the forecast period, North America is expected to hold the largest market share, supported by established veterinary healthcare infrastructure, substantial companion animal healthcare expenditure, and broad availability of prescription treatments. The United States represents a major market for veterinary pharmaceuticals and biological therapies, supported by established animal health companies, specialist veterinary practices, and product distribution networks. Regulatory approvals and commercial availability of established osteoarthritis medicines contribute to treatment accessibility. Furthermore, increasing attention to senior pet care, routine veterinary examinations, and chronic disease management supports demand for pharmaceutical interventions, joint supplements, and rehabilitation services. These factors reinforce North America's leading position in the pet osteoarthritis treatment market.

Region with highest CAGR:

The Asia Pacific region is expected to witness the highest CAGR during the forecast period, driven by increasing companion animal ownership, expanding veterinary service networks, rising disposable incomes, and growing awareness of animal health. Urbanization and changing household lifestyles are supporting expenditure on veterinary consultations, prescription medicines, and preventive healthcare. China, Japan, Australia, South Korea, and India offer opportunities for pharmaceutical manufacturers and veterinary service providers as access to specialized pet healthcare expands. Increasing availability of online veterinary pharmacies and growing professional awareness of chronic joint disorders are also supporting market development. These trends are expected to accelerate adoption of pet osteoarthritis treatments across the region.

Key players in the market

Some of the key players in the Global Pet Osteoarthritis Treatment Market include Zoetis Inc., Boehringer Ingelheim, Elanco Animal Health Incorporated, Dechra Pharmaceuticals PLC, Virbac, Vetoquinol S.A., Kindred Biosciences, American Regent Animal Health, Nutramax Laboratories Veterinary Sciences, Inc., and Assisi Animal Health.

Key Developments:

In October 2026, Boehringer Ingelheim announced the availability of its new Quarterable Snap-Tab design for PREVICOX (firocoxib) chewable tablets in the United States following FDA approval. The updated design enables tablets to be divided into quarters, providing more flexible dosing options based on dogs' body weight and improving convenience for veterinary professionals and pet owners.

In September 2026, Zoetis launched Lenivia (izenivetmab injection) in Great Britain. The long-acting monoclonal antibody therapy is designed to alleviate osteoarthritis-associated pain in dogs for up to three months following a single injection, expanding treatment options for canine chronic pain management.

In July 2026, Zoetis launched Lenivia in Canada and European Union member states. The commercial expansion increased the availability of its long-acting canine osteoarthritis treatment across additional veterinary markets and strengthened the company's targeted pain-management portfolio.

In July 2026, Zoetis launched Portela (relfovetmab) in Canada and the European Union. The long-acting anti-NGF monoclonal antibody therapy for cats is designed to provide osteoarthritis-associated pain relief for up to three months following a single subcutaneous injection, expanding biological treatment options for feline osteoarthritis.

Treatment Types Covered:

• Pharmaceuticals
• Biologics and Regenerative Therapies
• Nutraceuticals and Joint Supplements
• Rehabilitation and Physical Therapy

Drug Classes Covered:

• NSAIDs and Analgesics
• Anti-Nerve Growth Factor Therapies
• Other Pain-Management Drugs

Pet Types Covered:

• Dogs
• Cats

Distribution Channels Covered:

• Veterinary Hospitals and Clinics
• Veterinary Pharmacies
• Online Pharmacies

Regions Covered:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • Netherlands
  • Belgium
  • Sweden
  • Switzerland
  • Poland
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Malaysia
  • Singapore
  • Vietnam
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Colombia
  • Chile
  • Peru
  • Rest of South America
• Rest of the World (RoW)
  • Middle East
    • Saudi Arabia
    • United Arab Emirates
    • Qatar
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • Egypt
    • Morocco
    • Rest of Africa

What our report offers:

• Market share assessments for regional and country-level segments
• Strategic recommendations for new entrants
• Covers market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032, and 2034
• Market trends, including drivers, constraints, opportunities, threats, challenges, investment opportunities, and recommendations
• Strategic recommendations for key business segments based on market estimations
• Competitive landscape mapping and assessment of key industry trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends and assessment of the latest technological advancements

Free Customization Offerings:

All customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, forecasts, and CAGR of any prominent country as per the client's interest (subject to feasibility assessment)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances